Article Text
Abstract
Introduction Mechanical thrombectomy (MT) has become the standard treatment for acute ischemic stroke due to large vessel occlusions (LVO). However, MT may not result in successful recanalization due to underlying stenosis and bail-out stenting may achieve permanent recanalization.
Aim of Study To present the heal technology and the Credo heal Stent as an approach to intracranial atherosclerotic disease (ICAD) treatment and report the final results of a multicenter analysis.
Methods We retrospectively analysed data from 16 stroke centres. Patients treated with the Credo heal Stent were divided into two groups: symptomatic intracranial stenosis (sICAD) and persisting LVO due to underlying stenosis after futile mechanical thrombectomy (Rescue Stenting group). Primary endpoints were improvement of stenosis grade and rate of successful recanalization. Favourable neurological outcome was defined by modified Rankin Score at 90 days.
Results 121 patients were treated from 2021–2023 with the CREDO heal Stent. Rescue stenting and sICAD treatment was performed in 82 and 39 cases respectively. Overall, a final TICI ≥2b score was achieved in 94.5%. In 14% periprocedural complications occurred where in-stent thrombosis accounted for 6.3% (rescue stenting group). The mean stenosis grade in the sICAD group was 90% before and 15% after PTA and stenting. On follow-up (n=27) restenosis was observed in 2.8%.
Conclusion The Credo heal stent offers a treatment option for patients with sICAD or with persistent occlusion. The rate of restenosis is low compared to previous trials. Its effectiveness with regard to long-term ischemic complications will be evaluated in the prospective ReCHRUT trial.
Disclosure of Interest Hannes Nordmeyer and Franziska Dorn received speaker honoraria from Acandis. All other author have nothing to disclose.